Avp-786

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

SchizophreniaMajor Depressive Disorder

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

1

Avp-786

Otsuka

Phase 3

22

Ozempic

Novo Nordisk

Preclinical

13

Resotran

Takeda

Preclinical

14

Inapsine

Alnylam Pharmaceuticals

Preclinical

15

Zocor

OOrganon and Co

Preclinical

66

Ibrance

Pfizer

Preclinical

—7

Lunesta

Akero Therapeutics

Preclinical

38

Comtan

Orion Corporation, Orion Pharma

Preclinical

19

Luvox

SSolvay Pharmaceuticals

Preclinical

110

Vivarin

HHikma Pharmaceuticals LLC

Preclinical

1Show 24 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Agitation5 trials

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Terminated·Otsuka·Phase 3·NCT04464564·241 enrolled

Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Completed·Otsuka·Phase 3·NCT02442765·387 enrolled

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Terminated·Otsuka·Phase 3·NCT04408755·184 enrolled

Show 2 more trials

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Terminated·Otsuka·Phase 3·NCT02446132·1,197 enrolled

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Completed·Otsuka·Phase 3·NCT03393520·601 enrolled

Tics2 trials

A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers

Completed·AAvanir Pharmaceuticals·Phase 1·NCT02174835·56 enrolled

Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers

Completed·AAvanir Pharmaceuticals·Phase 1·NCT01787747·48 enrolled

Schizophrenia2 trials

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

Completed·AAvanir Pharmaceuticals·Phase 2·NCT02477670·145 enrolled

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

Terminated·Otsuka·Phase 2/3·NCT03896945·136 enrolled

Phase 11 trial

A Phase 1 Study Comparing AVP-786 With AVP-923

Completed·AAvanir Pharmaceuticals·Phase 1·NCT02336347·62 enrolled

Intermittent Explosive Disorder1 trial

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder

Terminated·Otsuka·Phase 2·NCT03420222·10 enrolled

4 more indications

Interaction1 trial

A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects

Completed·Otsuka·Phase 1·NCT02174822·56 enrolled

Treatment1 trial

Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition

Terminated·AAvanir Pharmaceuticals·Phase 2·NCT02534038·1 enrolled

Depressive Disorder, Treatment-Resistant1 trial

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Completed·AAvanir Pharmaceuticals·Phase 2·NCT02153502·206 enrolled

Adult Subject1 trial

A Phase 1, Single-center, Randomized, Double-blind, Double-dummy, Drug Interaction Study Between AVP-923 and Itraconazole, and Between AVP-786 and Itraconazole in Healthy Adult Subjects

Completed·AAvanir Pharmaceuticals·Phase 1·NCT02402595·24 enrolled

Details

Drug Info

Related News